| Popis: |
BackgroundDelayed onset of muscle soreness (DOMS) and its physiological consequences has an important influence on the individual’s adherence to the exercise routine.ObjectiveThis study aimed to evaluate the efficacy, safety, and tolerability of TurmXTRA® 60N (WDTE60N) on DOMS in comparison with placebo in recreationally active healthy subjects.MethodsThe present study was a randomized, double-blind, placebo-controlled parallel group study. Thirty healthy and recreationally active subjects (average age: 28.23±4.20 years) were randomized to receive WDTE60N (WDTE60N group; n=15) or placebo (placebo group; n=15). Study treatments were initiated 29 days prior to the eccentric exercise and continued for 4 days after the exercise. Primary endpoint was the change in pain intensity measured by the visual analog scale (VAS) at the end of study treatment (at 96 hours after eccentric exercise) from baseline (measured immediately after exercise).ResultsThe VAS score indicated that subjects from the WDTE60N group reported significantly less pain after eccentric exercise compared to placebo group (AUC0-96h: 286.8±46.7 vs. 460±40.5, respectively; p0-96h: 23623.7±2532.0 vs. 26138.6±3669.5, respectively; p=0.0446).ConclusionThe WDTE60N intake before and after eccentric exercise significantly reduced subjective perception of muscle soreness and serum LDH activity, and increased psychological wellbeing after eccentric exercise in recreationally active subjects. |
